Novo Nordisk's liraglutide recommended for EU approval
This article was originally published in Scrip
Executive Summary
Novo Nordisk's glucagon-like peptide-1 (GLP-1) analogue liraglutide has been recommended for approval by the EU's CHMP for the treatment of type 2 diabetes. It will be marketed as Victoza, with launch expected in a number of European countries this summer.